Cellectis (CLLS) Retained Earnings (2014 - 2026)
Cellectis' (CLLS) quarterly Retained Earnings came in at -$334.2 million in Q1 2026, down 1.4% year-on-year from -$338.9 million in Q1 2025, and down 25.38% quarter-over-quarter from -$266.5 million in Q4 2025.
Cellectis (CLLS) Retained Earnings (2014 - 2026) Analysis & Trends
Cellectis' Retained Earnings history runs 13 years deep, the most recent figure standing at -$334.2 million for Q1 2026.
- On a quarterly basis, Retained Earnings fell 1.4% year-over-year to -$334.2 million in Q1 2026; TTM through Mar 2026 was -$334.2 million, a 1.4% decrease from a year earlier, with the FY2025 full-year figure at -$266.5 million, up 8.98% from the prior year.
- Retained Earnings eased to -$334.2 million in Q1 2026 per CLLS's latest filing, from -$266.5 million in the prior quarter.
- Across five years, Retained Earnings topped out at -$266.5 million in Q4 2025 and bottomed at -$696.1 million in Q1 2022.
- The 5-year median for Retained Earnings is -$329.6 million (2025), against an average of -$353.5 million.
- Across the five-year window, Retained Earnings surged 45.28% in 2022 and sank 33.05% in 2024, its largest moves.
- Year by year, Retained Earnings stood at -$333.4 million in 2022, then increased by 8.6% to -$304.7 million in 2023, then grew by 3.89% to -$292.8 million in 2024, then increased by 8.98% to -$266.5 million in 2025, then fell by 25.38% to -$334.2 million in 2026.
- Per Business Quant, the three latest CLLS Retained Earnings figures stand at -$334.2 million (Q1 2026), -$266.5 million (Q4 2025), and -$266.6 million (Q3 2025).
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Retained Earnings (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 68,785.72 Bn | 68,785.72 Bn | - | -527.87 Mn |
| 2 | Nanobiotix | 1,895.57 Bn | 1,895.51 Bn | - | -27.89 Mn |
| 3 | BeOne Medicines | 471.35 Bn | 466.56 Bn | 1.35 Bn | 12.91 Bn |
| 4 | NuCana | 279.75 Bn | 279.75 Bn | - | 115.82 Mn |
| 5 | Vertex Pharmaceuticals | 120.24 Bn | 113.00 Bn | 2.59 Bn | 14.59 Bn |
| 6 | Regeneron Pharmaceuticals | 67.80 Bn | 59.04 Bn | 3.31 Bn | 11.90 Mn |
| 7 | Belite Bio | 62.51 Bn | 62.51 Bn | - | - |
| 8 | Argenx Se | 57.38 Bn | 57.38 Bn | 1.41 Bn | 1.41 Bn |
| 9 | Revolution Medicines | 37.78 Bn | 37.78 Bn | - | -622,000.00 |
| 10 | Cellectis | 281.48 Mn | 95.81 Mn | - | -334.17 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -334.17 Mn |
| Dec 31, 2025 | -266.54 Mn |
| Sep 30, 2025 | -266.59 Mn |
| Jun 30, 2025 | -266.59 Mn |
| Mar 31, 2025 | -329.56 Mn |
| Dec 31, 2024 | -292.85 Mn |
| Sep 30, 2024 | -405.80 Mn |
| Jun 30, 2024 | -405.73 Mn |
| Mar 31, 2024 | -405.81 Mn |
| Dec 31, 2023 | -304.71 Mn |
| Sep 30, 2023 | -304.99 Mn |
| Jun 30, 2023 | -305.39 Mn |
| Mar 31, 2023 | -439.22 Mn |
| Dec 31, 2022 | -333.37 Mn |
| Sep 30, 2022 | -330.60 Mn |
| Jun 30, 2022 | -320.81 Mn |
| Mar 31, 2022 | -696.06 Mn |
| Dec 31, 2021 | -584.13 Mn |
| Sep 30, 2021 | -586.72 Mn |
| Jun 30, 2021 | -586.28 Mn |